Table 3 Baseline demographic and treatment characteristics for the study groups of the PAM study
|  | Intervention group (n = 91) | Control group (n = 90) |
|---|---|---|
Age (years) | 52.1 (8.6) | 52.5 (8.7) |
Education level (n (%)) | ||
 High | 42 (46.2) | 36 (40.0) |
 Middle | 49 (53.8) | 52 (57.8) |
 Low | 0 (0) | 0 (0) |
 Missing | 0 (0) | 2 (2.2) |
Employment (n (%)) | ||
 Yes (full/part-time) | 51 (56.0) | 47 (52.2) |
 Temporarily work disabled | 6 (6.6) | 8(8.9) |
  < 100% | 3 (3.3) | 1 (1.1) |
  100% | 3 (3.3) | 7 (7.8) |
 Work disabled | 14 (15.4) | 15 (16.7) |
  < 35% | 0 (0) | 0 (0) |
  35–80% | 0 (0) | 5 (5.6) |
  > 80% | 14 (15.4) | 10 (11.1) |
 No | 17 (18.7) | 18 (20) |
 Missing | 3 (3.3) | 2 (2.2) |
Physical fitness (VO2peak in ml/min/kg) | 23.6 (4.7) | 24.9 (6.2) |
Menopausal status (n (%)) | ||
 Pre/peri | 10 (11.0) | 11 (12.2) |
 Post | 81 (89.0) | 79 (87.8) |
Age of menopause (years) | 47.4 (6.4) | 47.0 (5.5) |
Time since diagnosis (years)a | 3.1 (0.7) | 3.1 (0.6) |
Tumor grade (n (%)) | ||
 I | 11 (12.1) | 8 (8.9) |
 II | 36 (39.5) | 38 (42.2) |
 III | 31 (34.1) | 34 (37.7) |
 Unknown | 13 (14.3) | 10 (11.2) |
Surgery (n (%))a | ||
 Yes | 91 (100) | 89 (98.9) |
 Unknown |  | 1 (1.1) |
Chemotherapy timing (n (%)) | ||
 Neoadjuvant | 43 (47.3) | 43 (47.8) |
 Adjuvant | 44 (48.3) | 42 (46.7) |
 Both | 3 (3.3) | 3 (3.3) |
 Unknown | 1 (1.1) | 2 (2.2) |
Time since completion chemotherapy (years)a | 2.6 (0.7) | 2.6 (0.6) |
Radiation (n (%)) | ||
 Yes | 71 (78.0) | 65 (72.2) |
 No | 20 (22.0) | 24 (26.7) |
  Unknown |  | 1 (1.1) |
Targeted therapy (n (%)) | ||
 Yes | 19 (20.9) | 19 (21.1) |
 No | 72 (79.1) | 69 (76.7) |
 Unknown |  | 2 (2.2) |
Endocrine therapy (n (%)) | ||
 Yes | 57 (62.6) | 54 (60.0) |
 No | 34 (37.4) | 36 (40.0) |
Medication use (n (%)) | ||
 Cardiovascular | 18 (19.8) | 19 (21.1) |
 Anti-diabetic | 2 (2.2) | 2 (2.2) |
 Psychotropic | 30 (33.0) | 17 (18.9) |
 Pain medication | 13 (14.3) | 15 (16.7) |